Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial
for Friedreich’s ataxia

 

Companies to host conference call today at 8:30 a.m. ET

 

Boston, MA, and Bala Cynwyd, PA, December 18, 2019 – Zafgen, Inc. (Nasdaq:ZFGN) and
Chondrial Therapeutics, Inc., today announced they have entered into a definitive merger
agreement under which Chondrial will become a wholly-owned subsidiary of Zafgen and the
stockholders of Chondrial Therapeutics will become the majority owners of Zafgen’s
outstanding common stock upon the close of the merger. The proposed merger will result in a
combined publicly traded, clinical-stage biopharmaceutical company operating under a new
name, Larimar Therapeutics, Inc. (more…)

Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia and CTI-1601 granted Rare Pediatric Disease Designation and Fast Track Designation by U.S. FDA

BALA CYNWYD, PA – December 18, 2019 – Chondrial Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare diseases, with an initial focus on Friedreich’s ataxia (FA), today announced that the first patients have been dosed in a Phase 1 clinical trial to evaluate the safety and tolerability of single ascending doses of CTI-1601. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to patients with FA, who have decreased levels of frataxin. (more…)

Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich’s Ataxia

 

BALA CYNWYD, Pa.Aug. 3, 2017 — Chondrial Therapeutics, Inc., an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lead investigational drug candidate, CTI-1601, being developed for the treatment of Friedreich’s Ataxia.

(more…)

Chondrial Therapeutics Secures Up to $22.6 Million in Series A Financing and Licenses Novel Technology for the Treatment of Friedreich’s Ataxia

Company Plans to Advance Pipeline of Product Candidates Focused on the Treatment of Rare Mitochondrial Diseases

 

Carole Ben-Maimon, MD, Named President & CEO

 

Bala Cynwyd, PA – January 31, 2017 – Chondrial Therapeutics, Inc., an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, announced today that it has secured up to $22.6 million in Series A financing led by Deerfield Management and has appointed Carole Ben-Maimon, MD, as the company’s president and chief executive officer. (more…)